Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis
根据早前报道，Alnylam的Vutrisiran数据突出显示对关键心脏生物标志物的早期影响，Alnylam将首选用于ATTR淀粉样蛋白沉积症的一线治疗。
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which was held virtually. An open access recording of Alnylam presentations will be available on the HFSA website following the session.
纳斯达克(ALNY)领先的RNAi治疗公司Alnylam Pharmaceuticals, Inc.宣布，HELios-b Phase 3研究中vutrisiran的两组新数据集已在2024年心力衰竭学会(HFSA)年度科学会议Late Breaking Clinical Research Session 1上报告。该会议是以虚拟形式举行的。Alnylam的演示资料将在会后在HFSA网站上提供免费播放。
Progression in ATTR-CM is associated with cardiac wall thickening, deterioration in systolic and diastolic function and increases...
ATTR-Cm的进展与心脏壁增厚、收...
登录免费看全文
登录/注册
资讯热榜
更新时间